- Info
- Insider Trading
- Financials
- Holders: LYEL, LYEL
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL)
CUSIP: 55083R104
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 19,277,111
- Total 13F shares
- 692,050
- Share change
- +96,584
- Total reported value
- $21,301,299
- Price per share
- $30.78
- Number of holders
- 1
- Value change
- +$2,972,856
- Number of buys
- 1
Quarterly Holders Quick Answers
What is CUSIP 55083R104?
CUSIP 55083R104 identifies LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q3 2025
Recent filing periods for CUSIP 55083R104:
Top shareholders of LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Robert Nelsen |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
36,542,716
mixed-class rows
|
$83,020,992 | — | 14 Jun 2024 | |
| GSK plc |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
30,253,189
|
$68,977,271 | — | 21 Jun 2021 | |
| ARCH Venture Management, LLC |
13F
|
Company |
14%
|
2,759,072
|
$44,807,329 | — | 30 Sep 2025 | |
| ARCH Venture Fund IX, L.P. |
13D/G
|
— |
13%
|
2,759,072
|
$44,807,053 | $0 | 30 Sep 2025 | |
| Innovative Cellular Therapeutics Holdings Ltd |
13D/G
|
— |
9.8%
|
1,900,000
|
$30,855,810 | $0 | 06 Nov 2025 | |
| Foresite Capital Fund IV, L.P. |
13D/G
|
James B. Tananbaum |
7.6%
|
1,454,616
|
$23,622,818 | $0 | 30 Sep 2025 | |
| MWG Management Ltd. |
13F
|
Company |
5.3%
|
1,008,116
|
$16,371,804 | — | 30 Sep 2025 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
4.2%
|
800,399
|
$12,998,480 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.1%
|
779,004
|
$12,651,024 | — | 30 Sep 2025 | |
| Orland Properties Ltd |
13F
|
Company |
3.9%
|
754,698
|
$12,256,296 | — | 30 Sep 2025 | |
| NEWTON (PTC) Ltd |
13D/G
|
Newton (PTC) Limited |
3.9%
|
754,698
|
$12,256,220 | $0 | 30 Sep 2025 | |
| Hans Edgar Bishop |
3/4/5
|
Director |
—
mixed-class rows
|
4,815,614
mixed-class rows
|
$10,683,200 | — | 14 Jun 2024 | |
| Gates Frontier, LLC |
13D/G
|
— |
5.6%
|
1,040,964
|
$10,628,242 | $0 | 25 Jul 2025 | |
| Decheng Capital LLC |
13F
|
Company |
3.1%
|
595,466
|
$9,670,368 | — | 30 Sep 2025 | |
| Almitas Capital LLC |
13F
|
Company |
3%
|
577,807
|
$9,383,586 | — | 30 Sep 2025 | |
| Explore Investments LLC/DE |
13D/G
|
Explore Investments LLC |
5.4%
|
1,040,964
|
$9,202,122 | $0 | 25 Jul 2025 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
2.5%
|
477,078
|
$7,747,747 | — | 30 Sep 2025 | |
| venBio Partners LLC |
13F
|
Company |
2.5%
|
473,479
|
$7,689,299 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
4.5%
|
13,265,869
|
$6,234,958 | $0 | 31 Dec 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.8%
|
339,491
|
$5,513,334 | — | 30 Sep 2025 | |
| Alphabet Inc. |
13F
|
Company |
1.5%
|
293,256
|
$4,762,477 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.68%
|
130,257
|
$2,116,079 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.65%
|
125,361
|
$2,035,863 | — | 30 Sep 2025 | |
| Richard Klausner |
3/4/5
|
Director |
—
mixed-class rows
|
4,071,199
mixed-class rows
|
$1,791,262 | — | 15 May 2025 | |
| RBF Capital, LLC |
13F
|
Company |
0.5%
|
95,631
|
$1,553,047 | — | 30 Sep 2025 | |
| MIC Capital Management UK LLP |
13F
|
Company |
0.45%
|
87,028
|
$1,413,335 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.42%
|
79,510
|
$1,291,242 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.33%
|
63,990
|
$1,039,198 | — | 30 Sep 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
0.29%
|
54,887
|
$891,365 | — | 30 Sep 2025 | |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
|
Company |
0.28%
|
54,887
|
$891,365 | — | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.27%
|
51,727
|
$840,046 | — | 30 Sep 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.23%
|
43,799
|
$711,296 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.19%
|
37,020
|
$601,204 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.18%
|
33,752
|
$548,132 | — | 30 Sep 2025 | |
| CANADA PENSION PLAN INVESTMENT BOARD |
13F
|
Company |
0.15%
|
29,411
|
$477,635 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.15%
|
28,128
|
$456,798 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.11%
|
21,242
|
$344,970 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.11%
|
20,827
|
$338,230 | — | 30 Sep 2025 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.11%
|
20,800
|
$337,792 | — | 30 Sep 2025 | |
| Clarius Group, LLC |
13F
|
Company |
0.1%
|
19,958
|
$324,118 | — | 30 Sep 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.09%
|
18,000
|
$292,320 | — | 30 Sep 2025 | |
| Charles W. Newton |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
81,556
mixed-class rows
|
$290,086 | -$18,105 | 20 Aug 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.08%
|
16,159
|
$262,422 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.07%
|
13,128
|
$214,000 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.06%
|
12,234
|
$198,680 | — | 30 Sep 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.06%
|
11,390
|
$184,000 | — | 30 Sep 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.05%
|
10,275
|
$166,866 | — | 30 Sep 2025 | |
| Rangeley Capital, LLC |
13F
|
Company |
0.05%
|
10,000
|
$162,400 | — | 30 Sep 2025 | |
| Cathy Friedman |
3/4/5
|
Director |
—
mixed-class rows
|
596,370
mixed-class rows
|
$158,093 | — | 15 May 2025 | |
| Matthew Lang |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
218,750
mixed-class rows
|
$114,000 | — | 10 Feb 2025 |
Institutional Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) as of Q4 2025
As of 31 Dec 2025,
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
692,050 shares.
The largest 1 holders included
Decheng Capital LLC.
This page lists
1
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
2
Q4 2025 holders
1
Holder diff
-1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.